Skip to main content
Premium Trial:

Request an Annual Quote

Quark Delayed Graft Function Drug Gets European Orphan Drug Status

Premium

Quark Pharmaceuticals this week announced that its investigational drug for the prevention of delayed graft function in kidney transplant patients has received an orphan drug designation from the European Commission.

The provisions for the EU orphan designation provide incentives to companies developing the products, including the potential for up to 10 years of market exclusivity and various fee reductions for certain regulatory activities, Quark said.

The drug, QPI-1002, is designed to temporarily inhibit p53, and received a similar designation from the US Food and Drug Administration earlier this year.

Last month, Quark announced that phase I data for QPI-1002 showed the compound to be safe, with no dose-limiting toxicities (GSN 5/6/2010).

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.